Publications | PubMed=978138; DOI=10.1084/jem.144.4.873 Shiku H., Takahashi T., Oettgen H.F., Old L.J. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J. Exp. Med. 144:873-881(1976) PubMed=1067619; DOI=10.1073/pnas.73.9.3278 Carey T.E., Takahashi T., Resnick-Silverman L.A., Oettgen H.F., Old L.J. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976) PubMed=833871; DOI=10.1093/jnci/58.2.209 Fogh J., Wright W.C., Loveless J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58:209-214(1977) PubMed=6933476; DOI=10.1073/pnas.77.7.4260 Houghton A.N., Taormina M.C., Ikeda H., Watanabe T., Oettgen H.F., Old L.J. Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980) DOI=10.1007/978-1-4615-7228-2_39 Houghton A.N., Oettgen H.F., Old L.J. Malignant melanoma. Current status of the search for melanoma-specific antigens. (In) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston (1981) PubMed=7017212; DOI=10.1093/jnci/66.6.1003 Pollack M.S., Heagney S.D., Livingston P.O., Fogh J. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66:1003-1012(1981) PubMed=7175440; DOI=10.1084/jem.156.6.1755 Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med. 156:1755-1766(1982) PubMed=6864164; DOI=10.1084/jem.158.1.53 Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F., Old L.J. Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. J. Exp. Med. 158:53-65(1983) PubMed=6582512; DOI=10.1073/pnas.81.2.568 Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O. Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984) PubMed=2983346; DOI=10.1073/pnas.82.5.1470 Dracopoli N.C., Houghton A.N., Old L.J. Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985) PubMed=3518877; DOI=10.3109/07357908609038260 Fogh J. Human tumor lines for cancer research. Cancer Invest. 4:157-184(1986) PubMed=2499655; DOI=10.1084/jem.169.6.2029 Bouchard B., Fuller B.B., Vijayasaradhi S., Houghton A.N. Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J. Exp. Med. 169:2029-2042(1989) PubMed=2784858; DOI=10.1073/pnas.86.8.2804 Knuth A., Wolfel T., Klehmann E., Boon T., Meyer zum Buschenfelde K.-H. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc. Natl. Acad. Sci. U.S.A. 86:2804-2808(1989) PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22:157-163(1998) PubMed=17260012; DOI=10.1038/sj.onc.1210252 Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M., Guldberg P., Borg A. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 26:4738-4748(2007) PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958 Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M., Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R., Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E., Ostrer H., Osman I. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res. 71:2561-2571(2011) PubMed=21725359; DOI=10.1038/onc.2011.250 Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M., She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I., Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G., Wolchok J.D., Houghton A.N., Solit D.B. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31:446-457(2012) PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625 Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L., Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A., Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F., Rosen N., Solit D.B. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 74:2340-2350(2014) |